ORLANDO, FL—A new interim analysis of the ongoing ANNEXA-4 study evaluating andexanet alfa (AndexXa; Portola Pharmaceuticals) affirms that the drug rapidly reverses the anticoagulant effects of the ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

Dallas, TX - Initial clinical data has been reported on a direct Factor Xa inhibitor, a new and possibly improved approach to anticoagulation in angioplasty and ACS. The product, known as DX-9065a, is ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to andexanet alfa for the treatment of patients with serious, ...

Please provide your email address to receive an email when new articles are posted on . In recent years, medicine has witnessed the arrival of the direct oral anticoagulants, which include the direct ...

SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new in vitro data establishing the relationship between concentrations of the ...

Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Savaysa" report has been added to ResearchAndMarkets.com's offering. Savaysa (Edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for ...

Andexanet alfa is “a potential universal antidote for both direct and indirect factor Xa inhibitors”. This conclusion comes from the ANNEXA trials, the results of which were presented at the AHA ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a ...